You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
MBL will use the technology primarily for its diagnostic reagents business.
The technologies monitor patient response to immunotherapies.
Both companies plan to offer the test to researchers and clinicians to help better determine when a patient can be diagnosed with an infectious disease.
The non-exclusive licensing and distribution deal with Evolution Labs makes PolypDx available in five states.
The tests will enable clinicians to diagnose early-stage Alzheimer's disease more accurately by detecting biomarkers in cerebrospinal fluid.
The two firms will have the ability to develop instruments for commercialization within the IVD space.
The firm is developing a sepsis and SIRS diagnostic that combines its own molecule counting technology with Thermo Fisher's procalcitonin assay.
The firms have eliminated several terms of their original deal and have cross-licensed IP to allow Med BioGene to license Gene FX Lung to other firms.
The deal gives Bio-Rad licensing rights to a PCR-based platform and an assay that improves diagnostic sensitivity and efficacy across four dengue serotypes.
The technology is used in Qiagen's newly CE-marked test for cervical cancer and is complementary to human papillomavirus screening tests.